Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377853 | 0.86 | HDAC1 (0.54) | HDAC1HDAC8HDAC6PDE4BTP53 | |
| SCHEMBL12377867 | 0.83 | HDAC1 (0.51) | HDAC1HDAC8HDAC6TLR9TLR8 | |
| SCHEMBL12377859 | 0.82 | HDAC1 (0.58) | HDAC1HDAC8HDAC6PDE4BTP53 | |
| SCHEMBL10029551 | 0.78 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL12377852 | 0.77 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BTP53 | |
| SCHEMBL9900075 | 0.77 | ALDH1A1 (0.68) | HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL12377858 | 0.75 | HSD17B1 (0.48) | HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL3436645 | 0.75 | HDAC1 (0.65) | HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL12266902 | 0.71 | RAB9A (0.51) | TP53 | |
| SCHEMBL12678025 | 0.70 | NPC1 (0.66) | HDAC8HDAC6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | HDAC1 120/4885HDAC8 462/4885HDAC6 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.